Randomised trial to determine the safety and efficacy of early vs deferred treatment of HIV

确定艾滋病毒早期治疗与延迟治疗的安全性和有效性的随机试验

• 批准号: nhmrc : 1033140
• 负责人: A/Pr Edwina Wright
• 金额: $ 71.37万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-trial-determine-treatment-hiv/110883
• 关键词: Randomised; trial; determine; safety; efficacy

Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future research for many years to come.

艾滋病毒的治疗是医学研究的一项奇迹般的成就。全球使用抗逆转录病毒药物防止了大量发病和死亡。然而，目前还不清楚这些药物是否应该用于艾滋病毒阳性的早期艾滋病毒疾病，但没有临床症状的人。START试验将精确估计早期与晚期使用这些治疗的风险效益。它将立即影响世界各地的治疗指南，并为未来多年的研究提供信息。